@Neuralgroover They incorrectly use study criteria & endpoints as standards of care. For instance, in the ubro trials, it was required that patients have 4 migraine dys/mth to assure they would quickly have several chances to take the med. Now >=4 migraine dys/mth is required for the PA. BS!
Dr. Shane Miller with a first look at preliminary data from our study on #DHA following pediatric #concussion. Results show that it is feasible, safe, and may allow for shorter time to symptom-free state. Thanks to @BertVargas for organizing! @TxScottishRite
BREAKING NEWS: a second anti-CGRP treatment for Migraine prevention has been approved by the FDA. AJOVY should be available within 2 weeks. More: https://t.co/tR51XKOLpU
"Excitingly, the #CGRP receptor is not just a villain, but can also [have] beneficial outcomes. ... there is accumulating evidence that activation of the receptor could be used to treat inflammatory bowel disease, or resistant hypertension." #migraine
https://t.co/MDHfQqSvcm